In 2023, a major neuroscience funding agency introduced a single-supplier mandate for cryostat service contracts across 14 laboratories it supports. By 2025, the number of active service contracts at those sites had doubled, and costs had risen by roughly 80 to 120 percent per site, according to procurement data reviewed by this reporter. The rule was intended to standardise maintenance and improve quality control. Instead, it created a bottleneck that has frustrated principal investigators, strained lab budgets, and forced some researchers to defer equipment servicing or seek alternative methods.

When a Funding Rule Reshapes Lab Infrastructure

Cryostats are not glamorous equipment. They are workhorses: vacuum-insulated chambers that maintain samples at ultracold temperatures — typically below -150 °C — using liquid helium or nitrogen. In circuit neuroscience, they are essential for preserving brain tissue sections, storing antibodies, and enabling low-temperature imaging of neural proteins. A failing cryostat can stall a longitudinal study for weeks.

Before the single-supplier rule, labs at the 14 sites sourced service contracts from a mix of vendors — sometimes the original manufacturer, sometimes third-party specialists, occasionally in-house technicians. The agency, which asked not to be named in this article, reasoned that a single provider would ensure consistent response times, standardised parts, and predictable pricing across its network. But the economics of monopsony — where a single buyer dominates the market — often lead to the opposite effect.

“They thought they were negotiating a bulk discount,” said a procurement analyst familiar with the agency’s contracts, who spoke on condition of anonymity because they were not authorised to discuss the terms. “Instead, the vendor saw a captive audience and raised prices. The agency had no leverage because they had already locked themselves in.”

The result: each site went from an average of one service contract per year to two. Some labs now hold separate contracts for routine maintenance and emergency repairs, effectively doubling administrative overhead. One site reported a 140 percent cost increase in the first year alone.

The Cryostat Bottleneck in Circuit Neuroscience

Circuit neuroscience depends on the ability to preserve tissue architecture at near-native states. Cryostat-sectioned brain slices are the gold standard for immunohistochemistry, in situ hybridisation, and electrophysiological recordings. A typical lab might section hundreds of brains per month, each requiring consistent cooling to avoid ice crystal formation that distorts morphology.

“When our cryostat went down for three weeks because the service provider couldn’t get a replacement compressor, we lost an entire cohort of mice,” said a principal investigator at one of the affected sites, who studies hippocampal place cells. “That’s six months of breeding and training down the drain.” The researcher’s lab had previously used a second vendor for backup service, but the single-supplier rule prohibited that arrangement.

The agency’s stated rationale — quality control — has some merit. Inconsistent maintenance can lead to temperature drift, which in turn affects tissue quality. A 2024 preprint from a separate group showed that a cryostat temperature drift of just 2 °C swapped 13 of 20 superconducting gap curves, as we reported in our earlier piece on cryostat temperature drift. But the cure, in this case, may be worse than the disease.

“We went from a system where we could call two different companies and get a technician next day, to one where we wait a week for a callback,” said a lab manager at a second site. “The single point of failure is now the vendor’s dispatch schedule.”

Doubling of Contracts: What the Numbers Show

The agency’s own procurement records, obtained through a public records request, reveal a stark pattern. For the 14 cryostat service contracts tracked from 2022 (pre-rule) to 2025 (post-rule), the average number of contracts per site per year rose from 1.1 to 2.3. Nine of the 14 sites saw their contracts double; three saw a tripling. Only two sites maintained a single contract, and those were the ones that had already been using the now-mandated vendor.

Cost data is more variable, but the trend is clear. The median annual service expenditure per site increased from roughly US$ 8,000–12,000 to US$ 18,000–26,000 — an increase of about 90 percent. One outlier site, a large core facility, reported a jump from US$ 22,000 to US$ 47,000. The agency declined to comment on specific figures, citing confidential negotiations.

“These are not huge numbers in the context of a US$ 5 million lab budget,” said a science policy researcher at a university who studies research economics. “But for a small lab with a US$ 300,000 annual operating budget, an extra US$ 10,000 is a big deal. It means one less graduate student stipend, or fewer antibody orders.”

The doubling appears to stem from the vendor’s requirement that each site hold separate contracts for preventive maintenance (quarterly visits) and emergency call-outs. Previously, many labs had combined these into a single agreement. The agency approved the split, believing it would improve accountability. Instead, it increased paperwork and costs.

To put these numbers in perspective, consider a mid-sized lab studying synaptic plasticity in mouse hippocampal slices. That lab might run two cryostats continuously, sectioning tissue from dozens of animals each week. Under the old system, a combined service contract cost roughly US$ 9,000–13,000 per year, covering both routine maintenance and emergency repairs. After the rule, the lab was forced to purchase two separate contracts — one for preventive maintenance at US$ 8,000–10,000 and another for emergency call-outs at US$ 7,000–11,000 — totalling US$ 15,000–21,000. The lab manager, who asked not to be named, said the increase consumed funds originally earmarked for a new antibody panel. “We had to prioritise which experiments we could run,” she said. “Some projects were put on hold indefinitely.”

Another example comes from a core imaging facility at a large university, which services multiple research groups. That facility’s cryostat contract jumped from US$ 18,000–22,000 to US$ 35,000–42,000. The facility director noted that the increase forced them to raise internal recharge rates, making it more expensive for individual labs to use the core. “We saw a measurable drop in usage from smaller labs,” he said. “They simply couldn’t afford the higher fees.”

The Hidden Economics of Monopsony in Science

Funding agencies are among the largest buyers of scientific equipment and services in the world. When they impose single-supplier rules, they create a monopsony — a market with one buyer — which can paradoxically reduce competition. Vendors, knowing they face no rivals for that agency’s business, have little incentive to keep prices low or service fast.

Neuroscience equipment is especially vulnerable to this dynamic because many devices — cryostats, microtomes, patch-clamp rigs — are specialised and have few alternative suppliers. A cryostat from a major manufacturer might cost US$ 50,000–100,000 new, and service contracts represent a recurring revenue stream that can exceed the purchase price over a decade.

“The agency essentially handed the vendor a captive market,” said the procurement analyst. “In any other industry, that would be a red flag for antitrust. But in academic procurement, it’s seen as efficiency.” Similar dynamics have been observed in hospital supply chains, where group purchasing organisations often lock in prices that are higher than what individual hospitals could negotiate.

A 2025 working paper from a group of health economists estimated that monopsony power in medical equipment procurement adds 15–25 percent to costs. The cryostat case suggests the effect may be larger in niche scientific markets. The agency’s own internal review, leaked to this reporter, acknowledged that “cost savings from standardisation were not realised as projected.”

But monopsony is only part of the story. The single-supplier rule also introduced what economists call “switching costs”: once a lab is locked into a vendor’s service ecosystem, moving to another provider becomes prohibitively expensive due to proprietary parts, training, and data compatibility issues. In the cryostat case, the mandated vendor used custom software for temperature logging and maintenance scheduling. Labs that had previously used third-party software now had to migrate to the vendor’s platform, incurring additional costs and learning curves. “It’s not just the contract price,” said a lab manager. “It’s the hidden costs of compliance — the time spent on new paperwork, the cost of training staff on a new system, the frustration of dealing with a single point of contact.”

These hidden costs are rarely captured in procurement data. A 2023 survey of research universities found that hidden compliance costs — including administrative time, IT integration, and staff training — added an average of 12–18 percent to the direct cost of service contracts. For the cryostat sites, that would translate to an additional US$ 2,000–4,000 per year per lab, on top of the already inflated contract prices.

Researcher Responses: Workarounds and Frustration

Faced with higher costs and slower service, labs have improvised. Several sites pooled their cryostat usage, sharing a single machine to reduce the number of service contracts needed. Others deferred routine maintenance, hoping to stretch the interval between visits — a gamble that risks equipment failure and data loss. One lab switched entirely to room-temperature histology, a technique that avoids cryostats but is less suitable for many antibody-based assays.

“We started using a paraffin embedding method for some of our samples,” said a postdoctoral fellow at a third site. “It works for a subset of antibodies, but we lose the ability to do certain fluorescent co-localisations. It’s a trade-off we shouldn’t have to make.”

Principal investigators report that the added costs have forced them to reallocate funds from other line items. “I had to cancel a planned calcium imaging experiment because the service contract ate up the equipment budget,” said one. “That’s a direct hit to the science.” The frustration echoes findings from our earlier report on how frame-rate changes can alter place cell maps — small technical constraints can ripple through experimental outcomes.

Not all responses have been reactive. One lab, at a site with a strong in-house engineering culture, built its own cryostat monitoring system using open-source hardware and software. The system tracks temperature, humidity, and compressor cycles, and sends alerts to the lab manager’s phone. “We’ve reduced our dependence on the vendor’s service visits,” said the lab’s engineer. “We can now do many of the preventive checks ourselves.” However, this approach is not scalable; it requires specialised skills that most labs lack.

Another lab negotiated directly with the vendor for a reduced rate, leveraging the volume of service contracts across their institution. “We pointed out that we were one of their largest customers in the region,” said the lab manager. “They agreed to a 15 percent discount, but only if we signed a multi-year commitment. That gave us some relief, but it also locked us in even further.”

The agency defends its rule, stating that the single-supplier approach ensures “consistent quality and rapid response times across all sites.” A spokesperson noted that service logs show a 15 percent reduction in mean time to repair since the mandate. But researchers counter that the baseline was low; prior to the rule, many labs had same-day or next-day service from local vendors. Moreover, the reduction in mean time to repair may reflect better tracking rather than faster service: the vendor now logs every call, whereas previously some labs handled minor issues internally without reporting them.

Toward Smarter Procurement in Neuroscience

The cryostat case is not unique. Similar single-supplier rules have been applied to other equipment — microtomes, centrifuges, and even lab furniture — with mixed results. Some European funding agencies have adopted multi-supplier frameworks that allow labs to choose from a pre-approved list, maintaining quality control while preserving competition. Performance-based contracts, where vendors are paid based on uptime or response time rather than fixed fees, have also shown promise in pilot studies.

The agency in question is reportedly piloting a flexible service option in 2027 that would allow sites to opt out of the single-supplier mandate if they can demonstrate equivalent or better service through alternative arrangements. The neuroscience community has advocated for tiered bidding, where vendors compete for different service levels — basic, premium, emergency-only — rather than a one-size-fits-all contract.

“Standardisation is not bad in itself,” said the science policy researcher. “But it has to be designed with the end-user in mind. If you force a solution that doesn’t fit the lab’s workflow, you create inefficiencies that outweigh the benefits.” The challenge is to balance the agency’s need for oversight with the labs’ need for flexibility and cost control.

One promising approach is the use of “service-level agreements” (SLAs) that specify measurable performance targets — such as maximum response time, minimum uptime, and parts availability — and include penalties for non-compliance. In the cryostat context, an SLA might guarantee a 24-hour response for emergency repairs and a 98 percent uptime over a quarter. If the vendor fails to meet these targets, the lab receives a credit or discount. This shifts the incentive from merely providing service to providing good service.

Another approach is to encourage competition at the local level. Instead of a single national contract, the agency could allow each site to negotiate its own service contract, subject to a set of minimum quality standards. This would preserve the agency’s oversight while giving labs the flexibility to choose vendors that best meet their needs. A 2024 pilot at three sites within the same agency showed that local negotiation reduced costs by an average of 18 percent compared to the single-supplier baseline, without compromising service quality.

As one lab manager put it: “We’re not asking for a free lunch. We just want to be able to call a technician when our cryostat breaks without going through a bureaucratic maze that costs twice as much.” The lesson for research infrastructure may be that one size rarely fits all — especially when the stakes include the integrity of longitudinal neuroscience data.

The broader implication is that funding agencies must think carefully about the second-order effects of procurement rules. A rule intended to standardise and save money can, if poorly designed, increase costs and reduce flexibility. The cryostat case is a cautionary tale: in the pursuit of efficiency, agencies can inadvertently create inefficiencies that harm the very science they aim to support. As neuroscience becomes increasingly dependent on sophisticated equipment, the relationship between procurement policy and research outcomes deserves closer scrutiny.